41st Annual Report of Sandu Pharmaceuticals Limited

SANDU PHARMACEUTICALS LIMITED SI;:‘P/DU CIN:L24233GA1985PLC001587 Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +91 832 24074/7 4 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Ref: Corp.sec/2026-27/BSE/476 Department of Corporate Services Bombay Stock Exchange Limited, Phirojshah Jeejobhoy tower, Dalal Street, Mumbai-400001 Date: 19/08/2026 Sub: 41t Annual Report of Sandu Pharmaceuticals Limited pursuant to Regulation 34(1) of SEBI (LODR) Regulation 2015. Sir, In terms of Regulation 34(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we enclose herewith Annual report 2026-27 and Notice of the 41st Annual General Meeting (AGM) of the Company that is scheduled to be held on Friday, 11" September 2026 at 04.30 PM IST through Video Conferencing or other audio visual means (VC/OAVM). Today, the Company has initiated the process of sending Notice of the AGM through electronic mode to those shareholders whose names were recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories. The Company has uploaded the Annual Report 2026-27 along with Notice of the AGM and Rest Statutory Reports on its website: https://sandu.in/annual-report-2/. Kindly take the aforesaid information on record in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Yours Faithfully, FOR SANDU PHARMACEUTICALS LIMITED. Pratika Mhambray Company Secretary ACS:36512 Encl: - As Above AN 1SO 9001:2015 CERTIFIED ORGANISATION /",ul Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071. Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in "Jm/ TTTTTTTTTTTTTTTTT . ANNUAL REPORT 2025-2026 | SANDU PHARMACEUTICALS LIMITED Tribute to Late Shri Umesh B. Sandu Managing Director “Sincere appreciation and profound gratitude for his valuable contribution, exemplary leadership and dedicated service” SANDU PHARMACEUTICALS LIMITED Sandu Pharmaceuticals Limited CHAIRMAN SPEECH Dear Shareholders, Customers, Employees, and Well-Wishers, It gives me immense pleasure to present the 41st Annual Report of Sandu Pharmaceuticals Limited for the financial year 2025-26. This report reflects the Company’s performance, achievements, challenges, and progress during the year, while also outlining our vision and strategic priorities for the future. The past year has been significant not only for our Company but also for the Ayurvedic and wellness industry as a whole. Across the world, there is a growing appreciation for natural, preventive, and holistic healthcare solutions. Ayurveda, India’s timeless system of medicine, is increasingly being recognized as a credible and effective approach to health and well-being. As a company deeply rooted in Ayurvedic traditions, we are proud to contribute to this transformation and to the growing acceptance of Ayurveda among consumers globally. Reflecting on Our Journey The financial year 2025-26 was marked by both challenges and opportunities. In a dynamic business environment, we remained focused on our core values, customer trust, product quality, and operational excellence. Our resilience, adaptability, and commitment to Ayurvedic healthcare enabled us to navigate uncertainties while continuing to serve our customers effectively. Throughout the year, we strengthened our business foundations, enhanced operational efficiencies, and remained dedicated to delivering authentic and effective Ayurvedic products. These efforts have reinforced our position as a trusted name in the Ayurvedic healthcare sector. Financial Performance During the year under review, the Company’s revenue stood at ₹6,993.45 lakhs as compared to the previous year. Despite market challenges, the Company recorded an increase in net profit of 23.187%, reflecting improved operational efficiencies, prudent cost management, and the continued confidence of our customers in our products and services. Our strong financial position has enabled us to continue investing in key growth initiatives, including research and development, modernization of infrastructure, digital transformation, and brand-building activities. Innovation and Product Development Innovation continues to be a cornerstone of our growth strategy. Our research and development efforts focus on integrating traditional Ayurvedic wisdom with modern scientific methodologies to create products that are safe, effective, and relevant to contemporary healthcare needs. During the year, we continued to strengthen our product portfolio and invest in quality enhancement initiatives. The encouraging response from consumers reinforces our commitment to developing innovative Ayurvedic solutions that address evolving health and wellness requirements. Commitment to Sustainability Sustainability remains deeply embedded in our business philosophy. We are committed to conducting our operations responsibly while minimizing our environmental impact. Our initiatives include the adoption of eco-friendly practices, responsible sourcing of raw materials, resource conservation measures, and efforts to improve energy efficiency across our operations. We also remain committed to supporting the communities in which we operate through various social responsibility initiatives focused on health, education, and community welfare. We firmly believe that sustainable growth can only be achieved by balancing economic success with environmental stewardship and social responsibility. Looking Ahead As we move forward, we remain optimistic about the future and confident in our ability to create long-term value for all stakeholders. Our strategic priorities for the coming year include: Fourty One Annual Report 2025-26 1. Market Expansion We aim to strengthen our presence in existing markets while exploring new opportunities both within India and internationally. Through digital platforms, enhanced distribution networks, and strategic partnerships, we seek to make quality Ayurvedic healthcare accessible to a broader audience. 2. Research and Innovation We will continue to invest in research and development to expand and strengthen our product portfolio. Our focus will remain on delivering innovative, scientifically validated, and high-quality Ayurvedic solutions. 3. Customer-Centric Growth Our customers remain at the heart of everything we do. We will continue to enhance customer engagement, improve service standards, strengthen distribution channels, and deepen our understanding of consumer needs to deliver superior value and satisfaction. 4. Sustainable Business Practices We remain committed to advancing sustainability initiatives, promoting responsible sourcing, supporting sustainable farming practices, and contributing positively to society and the environment. Conclusion I would like to express my sincere gratitude to our shareholders for their continued trust and support. I also thank our customers for their confidence in our products and our business. Most importantly, I extend my appreciation to our employees whose dedication, commitment, and hard work have been instrumental in the Company’s success. Together, we have navigated challenges, achieved important milestones, and strengthened the foundation for future growth. With your continued support, I am confident that Sandu Pharmaceuticals Limited will continue to grow, innovate, and contribute meaningfully to the advancement of Ayurvedic healthcare. Thank you for your trust and partnership. I look forward to another year of progress, innovation, and sustainable growth. Warm regards, Sd/- CA Balram Viswanathan Chairman and Managing Director DIN: 10245195 Sandu Pharmaceuticals Limited Sandu Pharmaceuticals Limited CORPORATE INFORMATION SOLICITORS & ADVOCATES INTERNAL AUDITORS CIN L24233GA1985PLC001587 Website www.sandu.in M/s Madekars & Co M/s Akhil Pai & Co Advocates & Solicitors Engineer CT1, Block C, Garden [Showing first 8,000 characters — download PDF for full document]